Company: XERI
Filing Date: 2025-10-02
Form Type: 10-K
Source: 0001477932-25-007303
Chunk: 614

Company: XERIANT, INC.
Filing Date: 2025-10-02
Form: 10-K
Item: Item 7
Chunk 614
---
  309,107   282,249 Professional fees  221,119   308,109 Research and development expense  69,274   196,422 Total operating expenses  1,365,491   1,905,908          Loss from operations  (1,365,491)  (1,905,908)         Other expenses:        Amortization of debt discount  (51,006)  (19,189)Interest expense  (225,566)  (1,183,885)Loss on extinguishment of debt  (4,835)  (20,298)Gain on extinguishment of debt  -   28,627 Change in fair value of convertible bridge loans  -   (2,448)Total other expense  (281,407)  (1,197,193)         Net loss before income tax expense  (1,646,898)  (3,103,101)         Income tax expense  -   -          Net loss  (1,646,898)  (3,103,101)         Less net loss attributable to noncontrolling interest  (17,207)  (32,647)         Net loss attributable to common stockholders $(1,629,691) $(3,070,454)         Net loss per common share - basic and diluted $(0.00) $(0.01)         Weighted average number of common shares outstanding - basic and diluted  620,875,226   443,262,234 

The accompanying notes are an integral part of these consolidated financial statements. 

 F-4Table of Contents

XERIANT, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

   Series A Preferred Stock    Series B Preferred Stock    Common Stock   Common stockto be  Additional Paid-In   Accumulated   Non-Controlling     Shares   Amount   Shares   Amount   Shares   Amount   Issued   Capital   Deficit   Interest    Total  Balance June 30, 2023